Cardiovascular diseases (CVDs) represent the primary global
cause of mortality annually. Numerous distinct risk factors contribute to the
development of CVD, such as hypertension, age, smoking, insulin resistance,
obesity, elevated concentrations of low density lipoprotein-cholesterol, as
well as reduction of high density lipoprotein-cholesterol (HDL-C) levels.
Traditional markers of CVD have been insufficient to accurately predict
atherogenic risk, promoting the search of novel markers such as lipoprotein associated
phospholipase A2 (Lp-PLA2), considered a marker of vascular specific
inflammation and HDL functionality. Among the risk factors for CVD, obesity
represents one of particular importance given that its prevalence has increased
notably on a global scale. In addition to adults, obesity has become highly
prevalent in pediatric populations. Importantly, childhood obesity and related
complications can track into adulthood. Furthermore, the atherogenic process
starts early in life and the status of these new markers of CVD risk has been
insufficiently described in children and adolescents, particularly in the
context of childhood obesity. In the different studies carried out by our
group, we showed alterations in vascular inflammation, and different cardioprotective
functions of HDL suggesting an increase in atherogenic risk in obese pediatric
populations even at early age. These alterations would be present in both
general and abdominal specific obesity and could extend beyond alterations in
traditional markers such as lipid profile. The purpose of this chapter is to
highlight the status of these markers in childhood obesity.
Author(s) Details:
Davico, Belen,
Department of Clinical Biochemistry, School of Pharmacy and
Biochemistry, University of Buenos Aires, Argentina.
Lozano
Chiappe, Ezequiel,
Department
of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of
Buenos Aires, Argentina.
Gomez Rosso, Leonardo,
Department of Clinical Biochemistry, School of Pharmacy and
Biochemistry, University of Buenos Aires, Argentina.
Ballerini, Gabriela,
Department of Clinical Biochemistry, School of Pharmacy and
Biochemistry, University of Buenos Aires, Argentina.
Boero, Laura,
Department
of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of
Buenos Aires, Argentina.
MartÃn,
Maximiliano,
Department
of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of
Buenos Aires, Argentina.
Brites, Fernando,
Department of Clinical Biochemistry, School of Pharmacy and
Biochemistry, University of Buenos Aires, Argentina.
Please see the link here: https://stm.bookpi.org/ANUMS-V3/article/view/13158
No comments:
Post a Comment